MitoQ

The results are in: sharing our Longevity investment survey

Latest articles

A better model organism for testing antiaging drugs?

Harvard researcher proposes the Daphnia water flea as an alternative to worms for building a scalable platform for antiaging drugs research. In many ponds and...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

What the aging field needs

Changing the narrative – Celine Halioua reveals why the aging field needs to be taught some new tricks. Celine Halioua is the Founder and CEO...

Insilico Medicine gets $255m boost for AI-powered R&D

Insilico closes $255 million to progress into human clinical trials and develop novel targets and also announces Teva Pharm collaboration. Insilico Medicine, a company driving...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...
fundraising

Editor's picks

A better model organism for testing antiaging drugs?

Harvard researcher proposes the Daphnia water flea as an alternative to worms for building a scalable platform for antiaging drugs research. In many ponds and...

Small is mighty when it comes to mitochondria supplements

Optimise, energise, revitalise – MitoQ is on a mission to supplement your mitochondrial health. Coenzyme Q10 – or CoQ10 – is made naturally in the...

What the aging field needs

Changing the narrative – Celine Halioua reveals why the aging field needs to be taught some new tricks. Celine Halioua is the Founder and CEO...
MitoQ

Click the globe for translations.

There is rapidly-increasing activity in both the research and the investment communities that focus on Longevity; this survey gets into the details.

The global Longevity economy is projected to reach $27 trillion in 2026 – but timing is everything: demystifying the opportunity for investors and innovators, today, is paramount to achieving this growth:

For investors, the risk of missing-out on genuine Longevity funding opportunities increases as more (and less-valid) start-ups enter the market;

For early-stage Longevity start-ups, attracting investors with a genuine Longevity focus, and the funds to finance later rounds, is super-important.

This research was conducted in June 2020 and respondents were contacted as either subscribers to Longevity.Technology or as attendees to our Longevity 2020 digital event. With a very big thank you to all 133 of them, here are some key highlights (you can download the full report free from our store):

  • We asked both investors and investees about their focus to identify the alignment between investor appetite and current market activity. Interestingly, only agetech, AI and dietary supplements align in terms of activity and investor appetite;
  • Investing directly with founders (45%) reflects the early-stage nature of the Longevity investment category – where investors will probably have previously exited successful tech and/or biotech businesses and are now applying both their expertise and funds into direct investment;
  • The majority of respondents prefer to invest early. This aligns with the current (early) stage nature of the Longevity market and we expect later-stage investors to enter the market as confidence grows;
  • 38% of respondents are grant-funded, or pre-equity investment, which indicates the early-stage nature of many Longevity research and development areas; 32% are raising or have raised series A;
  • 60% of respondents are looking to raise within the next 5 months;
  • Respondents have raised an average of $1.86m in external funding to date.

Do download the full report (completely free) from our store – we’ll run this again later in the year to identify trends.

Thanks again to all those who participated.

Phil Newman
Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of First Longevity which brings together international investors and Longevity start-ups.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
MitoQ

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

Tree of Longevity – understanding how supplements work

Pathways? Hallmarks? Biomarkers? Understanding the longevity supplements lingo can help you make better choices for your healthspan. Longevity supplements differ from other 'generic supplements' as...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
fundraising

Related articles

Insilico Medicine gets $255m boost for AI-powered R&D

Insilico closes $255 million to progress into human clinical trials and develop novel targets and also announces Teva Pharm collaboration. Insilico Medicine, a company driving...

Longevity focused crypto platform to launch token auction

Lead researcher behind VitaDAO’s first project reveals more about his work and why crypto provides an exciting new funding option for longevity scientists. Later this...

Calling all longevity start-ups and scale-ups

Some news from us! Longevity.Technology's brand-new investment portal brings innovators and investors together. As a part of our mission to support the companies that will...

Oisín seed raise advances therapies for diseases of aging

Oisín Biotechnologies funding tops $9.5 million, with additional funding set to support preclinical development of its platform and investigational therapy for kidney and other age-related diseases. Seattle-based...

Dorian and HitGen to collaborate on senotherapy

Send in the senoblockers – Dorian and HitGen announce a research collaboration focused on DNA-encoded library-based drug discovery for age-related diseases. HitGen, Inc today announced...
MitoQ